cor2ed
engage checkpoint medical linkedin twitter
bg

Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Dr. Jaume Capdevila, Dr. Rachel van Leeuwaarde

Podcast with Dr. Jaume Capdevila and Dr. Rachel van Leeuwaarde discussing the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC).
Portrait of Jaume Capdevila
Dr. Jaume Capdevila

Medical Oncologist

Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...

Spain

Portrait of Rachel van Leeuwaarde
Dr. Rachel van Leeuwaarde

Endocrinologist

University Medical Centre Utrecht

Netherlands

preview next

time Podcast | open 20 min

Subscribe to our podcast series on:

download resources

THERE ARE NO DOWNLOADS FOR THIS PROGRAMME

I agree that this educational programme:

Was valuable to me:

1/3

In this episode, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.

This NET CONNECT podcast series is also available on CastosSpotifyApple Podcasts, and Google Podcasts.

Other programmes of interest